18. 脊髄小脳変性症(多系統萎縮症を除く。) Spinocerebellar degeneration Clinical trials / Disease details


臨床試験数 : 71 薬物数 : 101 - (DrugBank : 30) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 65

  
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-002812-36-ES
(EUCTR)
02/06/202119/11/2020A study to determine if Vatiquinone, the study drug, is safe and effective to treat a neurological condition called Friedreich ataxiaA Randomized, Parallel-Arm, Double-Blind, Placebo-Controlled Study with Open-Label Extension to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Friedreich ataxia (MOVE-FA) - MOVE-FA Friedreich Ataxia (FA)
MedDRA version: 20.0;Level: PT;Classification code 10017374;Term: Friedreich's ataxia;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Vatiquinone
Product Code: PTC743
INN or Proposed INN: VATIQUINONE
Other descriptive name: alpha-tocotrienolquinone
PTC Therapeutics, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
126Phase 2;Phase 3United States;France;Canada;Brazil;Spain;Australia;Germany;Italy
2EUCTR2020-002812-36-IT
(EUCTR)
14/04/202104/06/2021A study to determine if Vatiquinone, the study drug, is safe and effective to treat a neurological condition called Friedreich ataxiaA Randomized, Parallel-Arm, Double-Blind, Placebo-Controlled Study with Open-Label Extension to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Friedreich ataxia (MOVE-FA) - MOVE-FA Friedreich Ataxia (FA)
MedDRA version: 20.0;Level: PT;Classification code 10017374;Term: Friedreich's ataxia;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Vatiquinone
Product Code: [PTC743]
INN or Proposed INN: Vatiquinone
PTC THERAPEUTICS INC.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
126Phase 2;Phase 3France;United States;Canada;Spain;Brazil;Australia;Germany;Italy
3EUCTR2020-002812-36-FR
(EUCTR)
18/03/202115/01/2021A study to determine if Vatiquinone, the study drug, is safe and effective to treat a neurological condition called Friedreich ataxiaA Randomized, Parallel-Arm, Double-Blind, Placebo-Controlled Study with Open-Label Extension to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Friedreich ataxia (MOVE-FA) - MOVE-FA Friedreich Ataxia (FA)
MedDRA version: 20.0;Level: PT;Classification code 10017374;Term: Friedreich's ataxia;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Vatiquinone
Product Code: PTC743
INN or Proposed INN: VATIQUINONE
Other descriptive name: alpha-tocotrienolquinone
PTC Therapeutics, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
126Phase 2;Phase 3United States;France;Canada;Spain;Brazil;Australia;Germany;Italy;New Zealand
4EUCTR2020-002812-36-DE
(EUCTR)
18/02/202106/11/2020A study to determine if Vatiquinone, the study drug, is safe and effective to treat a neurological condition called Friedreich ataxiaA Randomized, Parallel-Arm, Double-Blind, Placebo-Controlled Study with Open-Label Extension to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Friedreich ataxia (MOVE-FA) - MOVE-FA Friedreich Ataxia (FA)
MedDRA version: 20.0;Level: PT;Classification code 10017374;Term: Friedreich's ataxia;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Vatiquinone
Product Code: PTC743
INN or Proposed INN: VATIQUINONE
Other descriptive name: alpha-tocotrienolquinone
PTC Therapeutics, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
126Phase 2;Phase 3France;United States;Canada;Spain;Brazil;Australia;Germany;Italy;New Zealand
5NCT04577352
(ClinicalTrials.gov)
December 17, 202030/9/2020A Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Participants With Friedreich AtaxiaA Randomized, Parallel-Arm, Double-Blind, Placebo-Controlled Study With Open-Label Extension to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Friedreich Ataxia (MOVE-FA)Friedreich AtaxiaDrug: Vatiquinone;Drug: PlaceboPTC TherapeuticsNULLActive, not recruiting7 YearsN/AAll146Phase 2/Phase 3United States;Australia;Brazil;Canada;France;Germany;Italy;New Zealand;Spain